Skip to the main content.

Breast Cancer

DESTINY-Breast09

Manufactured by: Daiichi Sankyo and AstraZeneca
Product name: ENHERTU® (trastuzumab deruxtecan)

About the DESTINY-Breast09 Trial

The DESTINY-Breast09 trial was a Phase 3, randomized, open-label, multicenter study evaluating the efficacy of trastuzumab deruxtecan (Enhertu) in combination with pertuzumab as a first-line treatment for patients with HER2-positive metastatic breast cancer. The study’s primary endpoint, progression-free survival (PFS), was met with statistically significant and clinically meaningful improvement compared to the standard regimen of taxane, trastuzumab, and pertuzumab (THP). Secondary endpoints, including overall survival (OS) and objective response rate (ORR), also trended favorably. Importantly, PFS benefits were consistent across all pre-specified patient subgroups, reinforcing the robustness of the findings. The safety profile of the Enhertu-pertuzumab combination was manageable and aligned with previously observed effects, without new safety signals. These results were presented at the 2024 ASCO Annual Meeting and have been highlighted by major opinion leaders, including Dr. Jame Abraham, further emphasizing the potential of this regimen as a new standard in the frontline management of HER2-positive metastatic breast cancer.

Table of Contents

Major Presentations and Milestones

DESTINY-Breast09 Trial design, results, and conclusions

DESTINY-Breast09 Sentiments and Criticisms

DESTINY-Breast09 Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

FDA approval signal (tweeted): Tatiana M. Prowell, MD: “#FDA has approved trastuzumab deruxtecan + pertuzumab for 1st line HER2+ metastatic breast cancer based on DB-09. This combo improved PFS by 13.8 mos (mPFS: 40.7 vs 26.9 mos)… ⚠️ ILD ~12%.” https://x.com/tmprowell/status/2000621007808409932

Tatiana M. Prowell, MD (additional regulatory resource): “Further info on 1st line trastuzumab deruxtecan + pertuzumab FDA approval…” https://x.com/tmprowell/status/2000644567318626467

DESTINY-Breast09 Trial: Major Presentations and Milestones

Primary speakers driving the story

DESTINY-Breast09 (DB-09) moved from “high expectation” to “practice-changing curves” during the ASCO 2025 cycle, then quickly into implementation debates (duration of ADC exposure, de-escalation, and ILD risk). Ahead of the meeting, OncoAlert flagged the trial as a top late-breaking abstract: “LBA1008: DESTINY-BREASTO9: TRASTUZUMAB DERUXTECAN (T-DXD) + PERTUZUMAB (P) VS TAXANE + TRASTUZUMAB …” https://x.com/OncoAlert/status/1925855609112437241

At ASCO 2025, ASCO’s meeting account summarized the headline magnitude: “Initial DESTINY-Breast09 results show 1L treatment w/ T-DXd + pertuzumab extends PFS by > 1 year compared w/ SOC THP.”

Paolo Tarantino, MD captured the “curves everybody’s been waiting for” moment with specific efficacy and response-depth metrics that rapidly circulated among breast oncology clinicians.

In parallel, a second “milestone” layer emerged as regulators and clinicians began to frame DB-09 as a new first-line standard, with Tatiana Prowell, MD explicitly linking the FDA decision to the magnitude of PFS benefit and the need to keep ILD risk front-of-mind. https://x.com/tmprowell/status/2000621007808409932

DESTINY-Breast09 Trial Design, Results, and Conclusions

Trial Design:

From the tweet dataset, DESTINY-Breast09 is a phase 3 first-line trial in HER2-positive metastatic breast cancer comparing trastuzumab deruxtecan (T-DXd) + pertuzumab versus standard-of-care THP (taxane + trastuzumab + pertuzumab). This is explicitly reflected in ASCO’s post (“…compared w/ SOC THP”) and in multiple clinician summaries. https://x.com/ASCO/status/1929524077913358696

Primary Results (PFS):

Paolo Tarantino, MD reported: “PFS … (40.7 vs 26.9 months, HR 0.56, p<0.001).” https://x.com/PTarantinoMD/status/1929519600942612950

Gaia Griguolo, MD reiterated the same median PFS values and emphasized subgroup consistency: “First-line T-DXd+P vs THP significantly prolongs PFS: 40.7 vs 26.9 mos … Benefit seen across subgroups.” https://x.com/GaiaGriguolo/status/1929520488256053619

Depth of response:

Tarantino highlighted response depth: “doubled the rate of complete responses (15% vs 8%).” https://x.com/PTarantinoMD/status/1929519600942612950

OS (immature):

OS was repeatedly described as immature. Tarantino described “a positive OS trend (HR 0.84).” https://x.com/PTarantinoMD/status/1929519600942612950

Griguolo similarly stated: “OS not mature.” https://x.com/GaiaGriguolo/status/1929520488256053619

PFS2 / post-progression therapy considerations:

Griguolo flagged downstream interpretability: “PFS2 benefit (10% received T-DXd after THP).” https://x.com/GaiaGriguolo/status/1929520488256053619

Nicole Casasanta, MD reported: “PFS2 not reached vs 36.5 m … OS immature.” https://x.com/ncasasanta/status/1929527133958725984

Safety (ILD as the dominant “real-world” concern):

While the dataset here does not include the full AE table, the community’s safety discourse centered on ILD risk with prolonged T-DXd exposure. Tatiana Prowell, MD explicitly included this in the FDA framing: “⚠️ ILD ~12%.” https://x.com/tmprowell/status/2000621007808409932

Key Conclusions:

Within the tweet corpus, DESTINY-Breast09 is being interpreted as a new first-line benchmark in HER2+ metastatic disease, with a large absolute PFS gain (40.7 vs 26.9 months; HR 0.56) and deeper responses (CR ~15% vs 8%). The immediate clinical “next questions” raised by KOLs are how to manage cumulative toxicity (especially ILD), how long to continue ADC-based induction, and whether/when to de-escalate to maintenance strategies (e.g., HP-based maintenance with tucatinib or endocrine/CDK4/6 approaches in HR+ disease).

DESTINY-Breast09 Sentiments and Criticisms

Positive Reception:

Paolo Tarantino, MD: “Practice changing data.” https://x.com/PTarantinoMD/status/1929519600942612950

Nicole Casasanta, MD: “🚨Practice changing interim results DESTINY-Breast09…” https://x.com/ncasasanta/status/1929527133958725984

Elisabetta Bonzano, MD, PhD emphasized presentation quality and subgroup consistency: “Stunning presentation ✨@stolaney1… PFS benefit… consistently observed across subgroups.” https://x.com/to_be_elizabeth/status/1929526114340192587

Critical Perspectives / Implementation Questions:

Stephanie Graff, MD, FACP, FASCO focused on duration and de-escalation: “the question will now be ‘for how long’ and possible if/when de-escalation strategies, knowing that many patients on THP were able to be on HP or H for a long time with near normal QoL.” https://x.com/DrSGraff/status/1914263511292641410

Dr. Kelly Shanahan highlighted the “brake” on enthusiasm from fatal toxicity: “But those 2 deaths from ILD…..” https://x.com/stage4kelly/status/1929570654912733457

Harold J. Burstein, MD, PhD, FASCO framed DB09 in the broader “move it earlier” debate: if patients will eventually receive the agent, the key question becomes whether earlier use truly improves outcomes, and how crossover/post-progression therapy affects interpretation. https://x.com/DrHBurstein/status/1927710221473812655

Broader oncology “ADC-first” context:

Tom Powles, MD (cross-tumor ADC perspective) used DB09 as an example of strong first-line ADC combination activity while cautioning that benefit may be tumor-specific: “Two ADC/PD1 combinations show +ve efficacy in 1st line breast cancer… DESTINY-B09 … ⬆️PFS… Activity maybe tumor specific.” https://x.com/tompowles1/status/1914682917239791797

DESTINY-Breast09 Temporal Sentiment Arc

April 2025 (early signal / expectation-setting)

Primary/KOL tweets:

May 2025 (ASCO25 preview and thematic framing)

Primary/KOL tweets:

June 2025 (ASCO25 presentation: efficacy enthusiasm + immediate safety/implementation debate)

Primary/KOL tweets:

Late 2025 (regulatory/practice consolidation)

Primary/KOL tweets:

Across the arc, DESTINY-Breast09 discourse progresses from expectation of superiority to confirmation with large PFS gains, then rapidly to implementation: balancing prolonged ADC exposure against QoL and ILD risk, and designing rational induction/maintenance/de-escalation pathways in a rapidly evolving 1L HER2+ metastatic landscape.

DESTINY-Breast09 Professional Resources